Education
About Us
Working with TipRanks
Follow Us
Pure Bioscience (PURE)
OTHER OTC:PURE
PURE Stock Chart & Stats
$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)
Day’s Range― - ―
52-Week Range$0.04 - $0.21
Previous CloseN/A
Volume1.63K
Average Volume (3M)53.72K
Market Cap
$6.72M
Enterprise Value$11.74M
Total Cash (Recent Filing)$509.00K
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding111,886,480
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00456
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.75
Enterprise Value/Revenue4.99
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-6.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthTTM revenue growth of 6.9% indicates persistent demand for the company’s SDC-based disinfectants across commercial and institutional channels. Sustainable top-line expansion improves the company’s ability to scale operations, spread fixed costs, and supports longer-term investment in product distribution and commercialization.
High Gross Margin ProfileA roughly 58% gross margin reflects strong unit economics for Pure Bioscience’s antimicrobial products, implying durable product-level profitability if production and procurement remain stable. High gross margins provide room to cover SG&A and R&D, making path to operating leverage more achievable if revenue keeps growing.
Expanded Capital-Structure FlexibilityShareholder approval to raise authorized common stock gives management structural flexibility to raise equity, grant compensation, or pursue strategic transactions to extend runway. This legally enables future financing or M&A options that can be critical to support operations and scale without changing the core business.
Bears Say
Negative Stockholders' EquityNegative shareholders’ equity signals a deteriorated capital base and materially limits financial flexibility. Over time this raises refinancing and going-concern risks, can increase borrowing costs, and may constrain the company’s ability to secure vendor terms or strategic partnerships without dilutive or costly recapitalization.
Persistent Cash BurnConsistent negative operating and free cash flow means the business relies on external capital to fund operations and growth. Ongoing cash burn increases the probability of future equity or debt raises, which can dilute shareholders or add leverage, and constrains reinvestment into sales, marketing, and R&D needed for durable expansion.
Structural UnprofitabilityDeeply negative operating results indicate gross profits are insufficient to cover operating costs. Unless operating expenses are reduced or revenue accelerates materially, the structural loss profile will persist, impairing the company’s ability to generate internally funded growth and increasing dependence on external financing.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.21 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $6.72M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Mar 18, 2026 which is in 14 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Dec 15, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 111,886,480 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 17.391%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
0.72% Other Institutional Investors
99.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---